Currently, there are three classes of anti-angiogenic drugs approved for the treatment of advanced NSCLC in China, including vascular endothelial growth factor inhibitor bevacizumab, small molecule multi-target tyrosine kinase inhibitor anlotinib, and recombinant human endostatin. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.